K Charlotte Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
K Charlotte Lee has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Adrien Al Wazzan
University of Rennes, CHU Rennes, Inserm, LTSI – UMR 1099 , F-35000 Rennes
1 shared publication - Benjamin Marut
CHU Rennes, Inserm, LTSI—UMR 1099, University of Rennes , 2 Rue Henri le Guilloux, Rennes F-35000
1 shared publication - Brian J. Czerniecki
Department of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
1 shared publication - Corentin Bourg
Department of Cardiology University of Rennes CHU Rennes Rennes France
1 shared publication - Erwan Donal
University of Rennes, CHU Rennes, Inserm, LTSI – UMR 1099 , F-35000 Rennes
1 shared publication Guillaume L’oFficial
CHU Rennes, Inserm, LTSI—UMR 1099, University of Rennes , 2 Rue Henri le Guilloux, Rennes F-35000
1 shared publication
Latest Publications
- 18 September 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 26 (2) , 239-248
Right ventricular free wall strain predicts transthyretin amyloidosis prognosis as well as biomarker-based staging systems
Aims: The diagnosis of transthyretin amyloidosis (ATTR) significantly impacts the management and prognosis of patients initially presenting with heart failure (HF). Despite recent advancements in treatment, prognosticating ATTR remains challenging. In this study, we aim to assess echocardiographic parameters associated with mid-term prognosis in patients with wild-type ATTR using a biomarker staging system as a reference point. Methods and results: We studied 182 consecutive patients with wild-type ATTR (91% male and median age 82 years) who were referred to our centre between 2016 and 2022. Using N-terminal pro-B-type natriuretic peptide and estimated glomerular filtration rate cut-offs, we classified patients into the following three stages: Stage I (101 patients, 55.5%), Stage II (53 patients, 29.0%), and Stage III disease (28 patients, 15.5%). We then compared traditional echocardiographic indices and markers of subclinical ventricular dysfunction [left ventricular (LV) global longitudinal strain, right ventricular (RV) free wall strain, and left atrial (LA) strain] among groups. Over a fixed follow-up period of 18 months, which included treatment with tafamidis 61 mg daily, 48 patients (26.4%) experienced the composite outcome of death or HF hospitalization. When compared with Stage I ATTR, the hazard ratio (HR) for death or hospitalization was 1.55 [95% confidence interval (CI) 0.62–3.86] for Stage II ATTR and 4.53 (95% CI 1.66–12.4, P = 0.0116) for Stage III ATTR. Among echocardiographic parameters, reduced RV free wall strrain (FWS) was independently associated with all-cause mortality or HF hospitalization after adjustment for the staging system (HR 2.03, 95% CI 1.07–3.85, P < 0.05). Conclusion: RV FWS should be routinely assessed for all patients with ATTR. It is an independent predictor of poor prognosis and provides additional value beyond biomarker staging systems.
- 18 September 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 26 (2) , 239-248
Right ventricular free wall strain predicts transthyretin amyloidosis prognosis as well as biomarker-based staging systems
Aims: The diagnosis of transthyretin amyloidosis (ATTR) significantly impacts the management and prognosis of patients initially presenting with heart failure (HF). Despite recent advancements in treatment, prognosticating ATTR remains challenging. In this study, we aim to assess echocardiographic parameters associated with mid-term prognosis in patients with wild-type ATTR using a biomarker staging system as a reference point. Methods and results: We studied 182 consecutive patients with wild-type ATTR (91% male and median age 82 years) who were referred to our centre between 2016 and 2022. Using N-terminal pro-B-type natriuretic peptide and estimated glomerular filtration rate cut-offs, we classified patients into the following three stages: Stage I (101 patients, 55.5%), Stage II (53 patients, 29.0%), and Stage III disease (28 patients, 15.5%). We then compared traditional echocardiographic indices and markers of subclinical ventricular dysfunction [left ventricular (LV) global longitudinal strain, right ventricular (RV) free wall strain, and left atrial (LA) strain] among groups. Over a fixed follow-up period of 18 months, which included treatment with tafamidis 61 mg daily, 48 patients (26.4%) experienced the composite outcome of death or HF hospitalization. When compared with Stage I ATTR, the hazard ratio (HR) for death or hospitalization was 1.55 [95% confidence interval (CI) 0.62–3.86] for Stage II ATTR and 4.53 (95% CI 1.66–12.4, P = 0.0116) for Stage III ATTR. Among echocardiographic parameters, reduced RV free wall strrain (FWS) was independently associated with all-cause mortality or HF hospitalization after adjustment for the staging system (HR 2.03, 95% CI 1.07–3.85, P < 0.05). Conclusion: RV FWS should be routinely assessed for all patients with ATTR. It is an independent predictor of poor prognosis and provides additional value beyond biomarker staging systems.
- 1 September 2014
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 219 (3) , S125-S126
Receptor Tyrosine Kinase Expression in BRCA Mutation Carriers: An Opportunity for Prevention of Invasive Breast Cancer
- 1 September 2014
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 219 (3) , S125-S126
Receptor Tyrosine Kinase Expression in BRCA Mutation Carriers: An Opportunity for Prevention of Invasive Breast Cancer